Non-viral Therapeutic Approaches to Ocular Diseases: An Overview and Future Directions

Overview

Journal J Control Release

Specialty Pharmacology

Date 2015 Oct 7

PMID 26439665

Citations 21

Authors

Rahel Zulliger

Shannon M Conley

Muna I Naash

Affiliations

Soon will be listed here.

Abstract

Currently there are no viable treatment options for patients with debilitating inherited retinal degeneration. The vast variability in disease-inducing mutations and resulting phenotypes has hampered the development of therapeutic interventions. Gene therapy is a logical approach, and recent work has focused on ways to optimize vector design and packaging to promote optimized expression and phenotypic rescue after intraocular delivery. In this review, we discuss ongoing ocular clinical trials, which currently use viral gene delivery, but focus primarily on new advancements in optimizing the efficacy of non-viral gene delivery for ocular diseases. Non-viral delivery systems are highly customizable, allowing functionalization to improve cellular and nuclear uptake, bypassing cellular degradative machinery, and improving gene expression in the nucleus. Non-viral vectors often yield transgene expression levels lower than viral counterparts, however their favorable safety/immune profiles and large DNA capacity (critical for the delivery of large ocular disease genes) make their further development a research priority. Recent work on particle coating and vector engineering presents exciting ways to overcome limitations of transient/low gene expression levels, but also highlights the fact that further refinements are needed before use in the clinic.

Citing Articles

Non-viral gene therapy for Leber's congenital amaurosis: progress and possibilities.

Abdulsalam L, Mordecai J, Ahmad I Nanomedicine (Lond). 2024; 20(3):291-304.

PMID: 39707712 PMC: 11792828. DOI: 10.1080/17435889.2024.2443387.

What's New in Ocular Drug Delivery: Advances in Suprachoroidal Injection since 2023.

Wu K, Gao A, Giunta M, Tran S Pharmaceuticals (Basel). 2024; 17(8).

PMID: 39204112 PMC: 11357265. DOI: 10.3390/ph17081007.

Effective intravitreal gene delivery to retinal pigment epithelium with hyaluronic acid nanospheres.

Crane R, Makia M, Zeibak S, Tebbe L, Ikele L, Woods C Mol Ther Nucleic Acids. 2024; 35(2):102222.

PMID: 38868364 PMC: 11168490. DOI: 10.1016/j.omtn.2024.102222.

Preformed Vesicle Approach to LNP Manufacturing Enhances Retinal mRNA Delivery.

Eygeris Y, Henderson M, Curtis A, Jozic A, Stoddard J, Reynaga R Small. 2024; 20(37):e2400815.

PMID: 38738752 PMC: 11661498. DOI: 10.1002/smll.202400815.

Seeing the Future: A Review of Ocular Therapy.

Whalen M, Akula M, McNamee S, Deangelis M, Haider N Bioengineering (Basel). 2024; 11(2).

PMID: 38391665 PMC: 10886198. DOI: 10.3390/bioengineering11020179.

References

Boyes J, Bird A . Repression of genes by DNA methylation depends on CpG density and promoter strength: evidence for involvement of a methyl-CpG binding protein. EMBO J. 1992; 11(1):327-33. PMC: 556453. DOI: 10.1002/j.1460-2075.1992.tb05055.x. View

. Assessment of adenoviral vector safety and toxicity: report of the National Institutes of Health Recombinant DNA Advisory Committee. Hum Gene Ther. 2002; 13(1):3-13. DOI: 10.1089/10430340152712629. View

Han Z, Banworth M, Makkia R, Conley S, Al-Ubaidi M, Cooper M . Genomic DNA nanoparticles rescue rhodopsin-associated retinitis pigmentosa phenotype. FASEB J. 2015; 29(6):2535-44. PMC: 4447225. DOI: 10.1096/fj.15-270363. View

Kalderon D, Roberts B, Richardson W, Smith A . A short amino acid sequence able to specify nuclear location. Cell. 1984; 39(3 Pt 2):499-509. DOI: 10.1016/0092-8674(84)90457-4. View

Storey P, Dollin M, Pitcher J, Reddy S, Vojtko J, Vander J . The role of topical antibiotic prophylaxis to prevent endophthalmitis after intravitreal injection. Ophthalmology. 2013; 121(1):283-289. DOI: 10.1016/j.ophtha.2013.08.037. View

Remaut K, Lucas B, Braeckmans K, Demeester J, De Smedt S . Pegylation of liposomes favours the endosomal degradation of the delivered phosphodiester oligonucleotides. J Control Release. 2006; 117(2):256-66. DOI: 10.1016/j.jconrel.2006.10.029. View

Aker M, Tubb J, Groth A, Bukovsky A, Bell A, Felsenfeld G . Extended core sequences from the cHS4 insulator are necessary for protecting retroviral vectors from silencing position effects. Hum Gene Ther. 2007; 18(4):333-43. DOI: 10.1089/hum.2007.021. View

Cideciyan A, Jacobson S, Beltran W, Sumaroka A, Swider M, Iwabe S . Human retinal gene therapy for Leber congenital amaurosis shows advancing retinal degeneration despite enduring visual improvement. Proc Natl Acad Sci U S A. 2013; 110(6):E517-25. PMC: 3568385. DOI: 10.1073/pnas.1218933110. View

Tanase J, Morohashi N, Fujita M, Nishikawa J, Shimizu M, Ohyama T . Highly efficient chromatin transcription induced by superhelically curved DNA segments: the underlying mechanism revealed by a yeast system. Biochemistry. 2010; 49(11):2351-8. DOI: 10.1021/bi901950w. View

10.

Zhu C, Zhang Y, Pardridge W . Widespread expression of an exogenous gene in the eye after intravenous administration. Invest Ophthalmol Vis Sci. 2002; 43(9):3075-80. View

11.

Roy K, Mao H, Huang S, Leong K . Oral gene delivery with chitosan--DNA nanoparticles generates immunologic protection in a murine model of peanut allergy. Nat Med. 1999; 5(4):387-91. DOI: 10.1038/7385. View

12.

Wu Z, Sun J, Zhang T, Yin C, Yin F, Van Dyke T . Optimization of self-complementary AAV vectors for liver-directed expression results in sustained correction of hemophilia B at low vector dose. Mol Ther. 2007; 16(2):280-9. DOI: 10.1038/sj.mt.6300355. View

13.

Parfitt D, Aguila M, McCulley C, Bevilacqua D, Mendes H, Athanasiou D . The heat-shock response co-inducer arimoclomol protects against retinal degeneration in rhodopsin retinitis pigmentosa. Cell Death Dis. 2014; 5:e1236. PMC: 4047904. DOI: 10.1038/cddis.2014.214. View

14.

Poloschek C, Bach M, Lagreze W, Glaus E, Lemke J, Berger W . ABCA4 and ROM1: implications for modification of the PRPH2-associated macular dystrophy phenotype. Invest Ophthalmol Vis Sci. 2010; 51(8):4253-65. DOI: 10.1167/iovs.09-4655. View

15.

Wroblewski J, Wells 3rd J, Eckstein A, Fitzke F, Jubb C, Keen T . Ocular findings associated with a 3 base pair deletion in the peripherin-RDS gene in autosomal dominant retinitis pigmentosa. Br J Ophthalmol. 1994; 78(11):831-6. PMC: 504967. DOI: 10.1136/bjo.78.11.831. View

16.

Sun Y, Jiao Y, Wang Y, Lu D, Yang W . The strategy to improve gene transfection efficiency and biocompatibility of hyperbranched PAMAM with the cooperation of PEGylated hyperbranched PAMAM. Int J Pharm. 2014; 465(1-2):112-9. DOI: 10.1016/j.ijpharm.2014.02.018. View

17.

Pitard B, Aguerre O, Airiau M, Lachages A, Boukhnikachvili T, Byk G . Virus-sized self-assembling lamellar complexes between plasmid DNA and cationic micelles promote gene transfer. Proc Natl Acad Sci U S A. 1998; 94(26):14412-7. PMC: 25002. DOI: 10.1073/pnas.94.26.14412. View

18.

Langer K, Balthasar S, Vogel V, Dinauer N, von Briesen H, Schubert D . Optimization of the preparation process for human serum albumin (HSA) nanoparticles. Int J Pharm. 2003; 257(1-2):169-80. DOI: 10.1016/s0378-5173(03)00134-0. View

19.

Voigt N, Henrich-Noack P, Kockentiedt S, Hintz W, Tomas J, Sabel B . Surfactants, not size or zeta-potential influence blood-brain barrier passage of polymeric nanoparticles. Eur J Pharm Biopharm. 2014; 87(1):19-29. DOI: 10.1016/j.ejpb.2014.02.013. View

20.

Rimann M, Luhmann T, Textor M, Guerino B, Ogier J, Hall H . Characterization of PLL-g-PEG-DNA nanoparticles for the delivery of therapeutic DNA. Bioconjug Chem. 2008; 19(2):548-57. DOI: 10.1021/bc7003439. View